Skip to main content

Advertisement

SpringerLink
Log in

Dysregulation of Synaptic Plasticity Markers in Schizophrenia

  • Review Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

Schizophrenia is a mental disorder characterized by cognitive impairment resulting in compromised quality of life. Since the regulation of synaptic plasticity has functional implications in various aspects of cognition such as learning, memory, and neural circuit maturation, the dysregulation of synaptic plasticity is considered as a pathobiological feature of schizophrenia. The findings from our recently concluded studies indicate that there is an alteration in levels of synaptic plasticity markers such as neural cell adhesion molecule-1 (NCAM-1), Neurotropin-3 (NT-3) and Matrix-mettaloproteinase-9 (MMP-9) in schizophrenia patients. The objective of the present article is to review the role of markers of synaptic plasticity in schizophrenia. PubMed database (http;//www.ncbi.nlm.nih.gov/pubmed) was used to perform an extensive literature search using the keywords schizophrenia and synaptic plasticity. We conclude that markers of synaptic plasticity are altered in schizophrenia and may lead to complications of schizophrenia including cognitive dysfunction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

BDNF:

Brain derived neurotrophic factor

GWAS:

Genome wide association study

ECM:

Extracellular matrix

LTP:

Long term potentiation

MCC:

Midcingulate cortex

MCCB:

The MATRICS consensus cognitive battery

MDD:

Major depressive disorder

MMP-9:

Matrix metalloproteinase-9

NCAM:

Neural adhesion molecule

NGF:

Nerve Growth Factor

NRXN:

Neurexin

NT3:

Neurotrophin-3

PSA:

Polysilic acid

PSD:

Post-synaptic density

SNP:

Single nucleotide polymorphism

TIMP:

Tissue inhibitor for matrix metalloproteinase

TRK:

Tropomyosin receptor kinase

References

  1. Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, et al. Schizophrenia. Nature Reviews Disease Primers. 2015;1:15067.

  2. Moradi H, Harvey PD, Helldin L. Correlates of risk factors for reduced life expectancy in schizophrenia: is it possible to develop a predictor profile? Schizophr Res. 2018;201:388–92.

    Article  Google Scholar 

  3. Sher L, Kahn RS. Suicide in schizophrenia: an educational overview. Medicina (Kaunas). 2019;55(7):361.

  4. Hany M, Rehman B, Azhar Y, Chapman J. Schizophrenia. In StatPearls. Treasure Island, FL: StatPearls; 2021. http://www.ncbi.nlm.nih.gov/books/NBK539864/ (Accessed on 25/10/2021).

  5. Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. Pharm Ther. 2014;39(9):638–45.

    Google Scholar 

  6. Citri A, Malenka RC. Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacol. 2008;33(1):18–41.

    Article  Google Scholar 

  7. Crabtree GW, Gogos JA. Synaptic plasticity, neural circuits, and the emerging role of altered short-term information processing in schizophrenia. Front Synaptic Neurosci. 2014;25(6):28.

    Google Scholar 

  8. Forsyth JK, Lewis DA. Mapping the consequences of impaired synaptic plasticity in schizophrenia through development: an integrative model for diverse clinical features. Trends Cogn Sci. 2017;21(10):760–78.

    Article  Google Scholar 

  9. Stephan KE, Baldeweg T, Friston KJ. Synaptic plasticity and dysconnection in schizophrenia. Biol Psychiatry. 2006;59(10):929–39.

    Article  CAS  Google Scholar 

  10. Berdenis van Berlekom A, Muflihah CH, Snijders GJ, MacGillavry HD, Middeldorp J, Hol EM, et al. Synapse pathology in schizophrenia: a meta-analysis of postsynaptic elements in postmortem brain studies. Schizophr Bull. 2020;46(2):374–86.

    Google Scholar 

  11. Zoladz PR, Park CR, Halonen JD, Salim S, Alzoubi KH, Srivareerat M, et al. Differential expression of molecular markers of synaptic plasticity in the hippocampus, prefrontal cortex, and amygdala in response to spatial learning, predator exposure, and stress-induced amnesia. Hippocampus. 2012;22(3):577–89.

    Article  CAS  Google Scholar 

  12. Föcking M, Lopez LM, English JA, Dicker P, Wolff A, Brindley E, et al. Proteomic and genomic evidence implicates the postsynaptic density in schizophrenia. Mol Psychiatry. 2015;20(4):424–32.

    Article  Google Scholar 

  13. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–7.

  14. MacDonald ML, Ding Y, Newman J, Hemby S, Penzes P, Lewis DA, et al. Altered glutamate protein co-expression network topology linked to spine loss in the auditory cortex of schizophrenia. Biol Psychiatry. 2015;77(11):959–68.

    Article  CAS  Google Scholar 

  15. Pennington K, Beasley CL, Dicker P, Fagan A, English J, Pariante CM, et al. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry. 2008;13(12):1102–17.

    Article  CAS  Google Scholar 

  16. Hill JJ, Hashimoto T, Lewis DA. Molecular mechanisms contributing to dendritic spine alterations in the prefrontal cortex of subjects with schizophrenia. Mol Psychiatry. 2006;11(6):557–66.

    Article  CAS  Google Scholar 

  17. Glausier JR, Lewis DA. Dendritic spine pathology in schizophrenia. Neuroscience. 2013;22(251):90–107.

    Article  Google Scholar 

  18. Garey L. When cortical development goes wrong: schizophrenia as a neurodevelopmental disease of microcircuits. J Anat. 2010;217(4):324–33.

    Article  Google Scholar 

  19. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677–736.

    Article  CAS  Google Scholar 

  20. Durany N, Michel T, Zöchling R, Boissl KW, Cruz-Sánchez FF, Riederer P, et al. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res. 2001;52(1–2):79–86.

    Article  CAS  Google Scholar 

  21. Buckley PF, Mahadik S, Pillai A, Terry A. Neurotrophins and schizophrenia. Schizophr Res. 2007;94(1):1–11.

    Google Scholar 

  22. Maisonpierre PC, Belluscio L, Squinto S, Ip NY, Furth ME, Lindsay RM, et al. Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science. 1990;247(4949 Pt 1):1446–51.

    Article  CAS  Google Scholar 

  23. Hernández-Echeagaray E. Neurotrophin-3 modulates synaptic transmission. Vitam Horm. 2020;114:71–89.

    Article  Google Scholar 

  24. Ammendrup-Johnsen I, Naito Y, Craig AM, Takahashi H. Neurotrophin-3 enhances the synaptic organizing function of TrkC–protein tyrosine phosphatase σ in rat hippocampal neurons. J Neurosci. 2015;35(36):12425–31.

    Article  CAS  Google Scholar 

  25. Gómez-Pineda VG, Torres-Cruz FM, Vivar-Cortés CI, Hernández-Echeagaray E. Neurotrophin-3 restores synaptic plasticity in the striatum of a mouse model of Huntington’s disease. CNS Neurosci Ther. 2018;24(4):353–63.

    Article  Google Scholar 

  26. Nanko S, Hattori M, Kuwata S, Sasaki T, Fukuda R, Dai XY, Yamaguchi K, Shibata Y, Kazamatsuri H. Neurotrophin-3 gene polymorphism associated with schizophrenia. Acta Psychiatr Scand. 1994;89(6):390–2. https://doi.org/10.1111/j.1600-0447.1994.tb01534.x.

    Article  CAS  Google Scholar 

  27. Dawson E, Powell JF, Sham PC, Nöthen M, Crocq MA, Propping P, et al. An association study of a neurotrophin-3 (NT-3) gene polymorphism with schizophrenia. Acta Psychiatr Scand. 1995;92(6):425–8.

    Article  CAS  Google Scholar 

  28. Hattori M, Kunugi H, Akahane A, Tanaka H, Ishida S, Hirose T, et al. Novel polymorphisms in the promoter region of the neurotrophin-3 gene and their associations with schizophrenia. Am J Med Genet. 2002;114(3):304–9.

    Article  Google Scholar 

  29. Sheldrick A, Camara S, Ilieva M, Riederer P, Michel TM. Brain-derived neurotrophic factor (BDNF) and neurotrophin 3 (NT3) levels in post-mortem brain tissue from patients with depression compared to healthy individuals-a proof of concept study. Eur Psychiatry. 2017;46:65–71.

    Article  CAS  Google Scholar 

  30. Keshri N, Nandeesha H, Rajappa M, Menon V. Matrix metalloproteinase-9 increases the risk of cognitive impairment in schizophrenia. Nord J Psychiatry. 2021;75(2):130–4.

    Article  Google Scholar 

  31. Arabska J, Łucka A, Strzelecki D, Wysokiński A. In schizophrenia serum level of neurotrophin-3 (NT-3) is increased only if depressive symptoms are present. Neurosci Lett. 2018;25(684):152–5.

    Article  Google Scholar 

  32. Wysokiński A. Serum levels of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) in depressed patients with schizophrenia. Nord J Psychiatry. 2016;70(4):267–71.

    Article  Google Scholar 

  33. Saruta J, Iida M, Kondo Y, To M, Hayashi T, Hori M, et al. Chronic stress induces neurotrophin-3 in rat submandibular gland. Yonsei Med J. 2012;53(6):1085–92.

    Article  CAS  Google Scholar 

  34. Poduslo JF, Curran GL. Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3. BDNF Mol Brain Res. 1996;36(2):280–6.

    Article  CAS  Google Scholar 

  35. Pan W, Banks WA, Kastin AJ. Permeability of the blood-brain barrier to neurotrophins. Brain Res. 1998;788(1):87–94.

    Article  CAS  Google Scholar 

  36. Di Carlo P, Punzi G, Ursini G. Brain-derived neurotrophic factor and schizophrenia. Psychiatr Genet. 2019;29(5):200–10.

    Article  Google Scholar 

  37. Favalli G, Li J, Belmonte-de-Abreu P, Wong AHC, Daskalakis ZJ. The role of BDNF in the pathophysiology and treatment of schizophrenia. J Psychiatr Res. 2012;46(1):1–11.

    Article  Google Scholar 

  38. Peng S, Li W, Lv L, Zhang Z, Zhan X. BDNF as a biomarker in diagnosis and evaluation of treatment for schizophrenia and depression. Discov Med. 2018;26(143):127–36.

    Google Scholar 

  39. Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry. 2003;60(8):804–15.

    Article  CAS  Google Scholar 

  40. Fu X, Wang J, Du J, Sun J, Baranova A, Zhang F. BDNF gene’s role in schizophrenia: from risk allele to methylation implications. Front Psychiatry. 2020;15(11):564277. https://doi.org/10.3389/fpsyt.2020.564277.

    Article  Google Scholar 

  41. Harrisberger F, Smieskova R, Schmidt A, Lenz C, Walter A, Wittfeld K, et al. BDNF Val66Met polymorphism and hippocampal volume in neuropsychiatric disorders: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2015;55:107–18.

    Article  CAS  Google Scholar 

  42. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112(2):257–69.

    Article  CAS  Google Scholar 

  43. Skibinska M, Groszewska A, Kapelski P, Rajewska-Rager A, Pawlak J, Dmitrzak-Weglarz M, et al. Val66Met functional polymorphism and serum protein level of brain-derived neurotrophic factor (BDNF) in acute episode of schizophrenia and depression. Pharmacol Rep. 2018;70(1):55–9.

    Article  CAS  Google Scholar 

  44. Tang X, Zhou C, Gao J, Duan W, Yu M, Xiao W, et al. Serum BDNF and GDNF in Chinese male patients with deficit schizophrenia and their relationships with neurocognitive dysfunction. BMC Psychiatry. 2019;19(1):254.

    Article  Google Scholar 

  45. Yang Y, Liu Y, Wang G, Hei G, Wang X, Li R, et al. Brain-derived neurotrophic factor is associated with cognitive impairments in first-episode and chronic schizophrenia. Psychiatry Res. 2019;273:528–36.

    Article  CAS  Google Scholar 

  46. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci. 2001;24:1217–81.

    Article  CAS  Google Scholar 

  47. McAllister AK, Katz LC, Lo DC. Neurotrophins and synaptic plasticity. Annu Rev Neurosci. 1999;22(1):295–318.

    Article  CAS  Google Scholar 

  48. Schinder AF, Poo M. The neurotrophin hypothesis for synaptic plasticity. Trends Neurosci. 2000;23(12):639–45.

    Article  CAS  Google Scholar 

  49. Neugebauer K, Hammans C, Wensing T, Kumar V, Grodd W, Mevissen L, Sternkopf MA, Novakovic A, Abel T, Habel U, Nickl-Jockschat T. Nerve growth factor serum levels are associated with regional gray matter volume differences in schizophrenia patients. Front Psychiatry. 2019;26(10):275. https://doi.org/10.3389/fpsyt.2019.00275.

    Article  Google Scholar 

  50. Bora E, Fornito A, Radua J, Walterfang M, Seal M, Wood SJ, et al. Neuroanatomical abnormalities in schizophrenia: a multimodal voxelwise meta-analysis and meta-regression analysis. Schizophr Res. 2011;127(1):46–57.

    Article  Google Scholar 

  51. Nakamura M, Nestor PG, Levitt JJ, Cohen AS, Kawashima T, Shenton ME, et al. Orbitofrontal volume deficit in schizophrenia and thought disorder. Brain. 2008;131(1):180–95.

    Article  Google Scholar 

  52. Xiong P, Zeng Y, Zhu Z, Tan D, Xu F, Lu J, et al. Reduced NGF serum levels and abnormal P300 event-related potential in first episode schizophrenia. Schizophr Res. 2010;119(1):34–9.

    Article  Google Scholar 

  53. Zakharyan R, Atshemyan S, Gevorgyan A, Boyajyan A. Nerve growth factor and its receptor in schizophrenia. BBA Clin. 2014;20(1):24–9.

    Article  Google Scholar 

  54. Parikh V, Evans DR, Khan MM, Mahadik SP. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr Res. 2003;60(2–3):117–23.

    Article  Google Scholar 

  55. Rønn LC, Hartz BP, Bock E. The neural cell adhesion molecule (NCAM) in development and plasticity of the nervous system. Exp Gerontol. 1998;33(7–8):853–64.

    Article  Google Scholar 

  56. Togashi H, Sakisaka T, Takai Y. Cell adhesion molecules in the central nervous system. Cell Adh Migr. 2009;3(1):29–35.

    Article  Google Scholar 

  57. Vukojevic V, Mastrandreas P, Arnold A, Peter F, Kolassa I-T, Wilker S, et al. Evolutionary conserved role of neural cell adhesion molecule-1 in memory. Transl Psychiatry. 2020;10(1):1–13.

    Article  Google Scholar 

  58. Sytnyk V, Leshchyns’ Ka I, Nikonenko AG, Schachner M. NCAM promotes assembly and activity-dependent remodeling of the postsynaptic signaling complex. J cell Biol. 2006;174(7):1071–85.

    Article  CAS  Google Scholar 

  59. Stork O, Welzl H, Wolfer D, Schuster T, Mantei N, Stork S, et al. Recovery of emotional behaviour in neural cell adhesion molecule (NCAM) null mutant mice through transgenic expression of NCAM180. Eur J Neurosci. 2000;12(9):3291–306.

    Article  CAS  Google Scholar 

  60. Sullivan PF, Keefe RSE, Lange LA, Lange EM, Stroup TS, Lieberman J, et al. NCAM1 and neurocognition in schizophrenia. Biol Psychiat. 2007;61(7):902–10.

    Article  CAS  Google Scholar 

  61. Keshri N, Nandeesha H, Rajappa M, Menon V. Relationship between neural cell adhesion molecule-1 and cognitive functioning in schizophrenia spectrum disorder. Ind J Clin Biochem. 2021; Available from: https://doi.org/10.1007/s12291-020-00937-y

  62. An H, Zhou L, Yu Y, Fan H, Fan F, Tan S, et al. Serum NCAM levels and cognitive deficits in first episode schizophrenia patients versus health controls. Schizophr Res. 2018;192:457–8.

    Article  Google Scholar 

  63. An H, Qin J, Fan H, Fan F, Tan S, Wang Z, et al. Decreased serum NCAM is positively correlated with hippocampal volumes and negatively correlated with positive symptoms in first-episode schizophrenia patients. J Psychiatr Res. 2020;1(131):108–13.

    Article  Google Scholar 

  64. Huntley GW. Synaptic circuit remodelling by matrix metalloproteinases in health and disease. Nat Rev Neurosci. 2012;13(11):743–57.

    Article  CAS  Google Scholar 

  65. Löffek S, Schilling O, Franzke C-W. Biological role of matrix metalloproteinases: a critical balance. Eur Respir J. 2011;38(1):191–208.

    Article  Google Scholar 

  66. Lepeta K, Kaczmarek L. Matrix metalloproteinase-9 as a novel player in synaptic plasticity and schizophrenia. Schizophr Bull. 2015;41(5):1003–9.

    Article  Google Scholar 

  67. Szklarczyk A, Lapinska J, Rylski M, McKay RDG, Kaczmarek L. Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J Neurosci. 2002;22(3):920–30.

    Article  CAS  Google Scholar 

  68. Rivera S, Khrestchatisky M, Kaczmarek L, Rosenberg GA, Jaworski DM. Metzincin proteases and their inhibitors: foes or friends in nervous system physiology? J Neurosci. 2010;30(46):15337–57.

    Article  CAS  Google Scholar 

  69. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci. 2005;6(12):931–44.

    Article  CAS  Google Scholar 

  70. Bozdagi O, Nagy V, Kwei KT, Huntley GW. In vivo roles for matrix metalloproteinase-9 in mature hippocampal synaptic physiology and plasticity. J Neurophysiol. 2007;98(1):334–44.

    Article  CAS  Google Scholar 

  71. Wright JW, Harding JW. Contributions of matrix metalloproteinases to neural plasticity, habituation, associative learning and drug addiction. Neural Plast. 2010;10(2009):e579382.

    Google Scholar 

  72. Seitz-Holland J, Seethaler M, Makris N, Rushmore J, Cho KIK, Rizzoni E, et al. The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study. Neuropsychopharmacology. 2022;47(2):524–30.

    Article  CAS  Google Scholar 

  73. Zaidel DW, Esiri MM, Harrison PJ. Size, shape, and orientation of neurons in the left and right hippocampus: investigation of normal asymmetries and alterations in schizophrenia. Am J Psychiatry. 1997;154(6):812–8.

    Article  CAS  Google Scholar 

  74. Walker MA, Highley JR, Esiri MM, McDonald B, Roberts HC, Evans SP, et al. Estimated neuronal populations and volumes of the hippocampus and its subfields in schizophrenia. Am J Psychiatry. 2002;159(5):821–8.

    Article  Google Scholar 

  75. Strzelecki D, Kałużyńska O, Szyburska J, Wysokiński A. MMP-9 serum levels in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study). Int J Mol Sci. 2016;17(7):1075.

    Article  Google Scholar 

  76. Dwir D, Giangreco B, Xin L, Tenenbaum L, Cabungcal J-H, Steullet P, et al. MMP9/RAGE pathway overactivation mediates redox dysregulation and neuroinflammation, leading to inhibitory/excitatory imbalance: a reverse translation study in schizophrenia patients. Mol Psychiatry. 2020;25(11):2889–904.

    Article  Google Scholar 

  77. Devanarayanan S, Nandeesha H, Kattimani S, Sarkar S. Relationship between matrix metalloproteinase-9 and oxidative stress in drug-free male schizophrenia: a case control study. Clin Chem Lab Med (CCLM). 2016;54(3):447–52.

    Article  CAS  Google Scholar 

  78. Lepeta K, Purzycka KJ, Pachulska-Wieczorek K, Mitjans M, Begemann M, Vafadari B, Kaczmarek L. A normal genetic variation modulates synaptic MMP-9 protein levels and the severity of schizophrenia symptoms. EMBO Mol Med. 2017;9(8):1100–16.

    Article  CAS  Google Scholar 

  79. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest. 1996;98(11):2572–9. https://doi.org/10.1172/JCI119076.

    Article  CAS  Google Scholar 

  80. Tromp A, Mowry B, Giacomotto J. Neurexins in autism and schizophrenia-a review of patient mutations, mouse models and potential future directions. Mol Psychiatry. 2021;26(3):747–60.

    Article  CAS  Google Scholar 

  81. Kirov G, Gumus D, Chen W, Norton N, Georgieva L, Sari M, et al. Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet. 2008;17(3):458–65.

    Article  CAS  Google Scholar 

  82. Missler M, Zhang W, Rohlmann A, Kattenstroth G, Hammer RE, Gottmann K, et al. Alpha-neurexins couple Ca2+ channels to synaptic vesicle exocytosis. Nature. 2003;423(6943):939–48.

    Article  CAS  Google Scholar 

  83. Etherton MR, Blaiss CA, Powell CM, Südhof TC. Mouse neurexin-1alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. Proc Natl Acad Sci USA. 2009;106(42):17998–8003.

    Article  CAS  Google Scholar 

  84. Owczarek S, Bang ML, Berezin V. Neurexin-neuroligin synaptic complex regulates schizophrenia-related DISC1/kal-7/Rac1 “signalosome.” Neural Plast. 2015;2015:167308.

    Article  Google Scholar 

  85. Kirov G, Grozeva D, Norton N, Ivanov D, Mantripragada KK, Holmans P, et al. Support for the involvement of large copy number variants in the pathogenesis of schizophrenia. Hum Mol Genet. 2009;18(8):1497–503.

    Article  CAS  Google Scholar 

  86. Kirov G, Rujescu D, Ingason A, Collier DA, O’Donovan MC, Owen MJ. Neurexin 1 (NRXN1) deletions in schizophrenia. Schizophr Bull. 2009;35(5):851–4.

    Article  Google Scholar 

  87. Rujescu D, Ingason A, Cichon S, Pietiläinen OPH, Barnes MR, Toulopoulou T, et al. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet. 2009;18(5):988–96.

    Article  CAS  Google Scholar 

  88. Ishizuka K, Yoshida T, Kawabata T, Imai A, Mori H, Kimura H, et al. Functional characterization of rare NRXN1 variants identified in autism spectrum disorders and schizophrenia. J Neurodev Disord. 2020;12(1):25.

    Article  Google Scholar 

  89. Calabrese F, Molteni R, Racagni G, Riva MA. Neuronal plasticity: a link between stress and mood disorders. Psychoneuroendocrinology. 2009;1(34):S208–16.

    Article  Google Scholar 

  90. Murakami S, Imbe H, Morikawa Y, Kubo C, Senba E. Chronic stress, as well as acute stress, reduces BDNF mRNA expression in the rat hippocampus but less robustly. Neurosci Res. 2005;53(2):129–39.

    Article  CAS  Google Scholar 

  91. Kim D-M, Leem Y-H. Chronic stress-induced memory deficits are reversed by regular exercise via AMPK-mediated BDNF induction. Neuroscience. 2016;2(324):271–85.

    Article  Google Scholar 

  92. Smith MA, Makino S, Kvetnansky R, Post RM. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci. 1995;15(3 Pt 1):1768–77.

    Article  CAS  Google Scholar 

  93. Aguayo FI, Pacheco AA, García-Rojo GJ, Pizarro-Bauerle JA, Doberti AV, Tejos M, et al. Matrix metalloproteinase 9 displays a particular time response to acute stress: variation in its levels and activity distribution in rat hippocampus. ACS Chem Neurosci. 2018;9(5):945–56.

    Article  CAS  Google Scholar 

  94. Smith MA, Makino S, Altemus M, Michelson D, Hong SK, Kvetnansky R, et al. Stress and antidepressants differentially regulate neurotrophin 3 mRNA expression in the locus coeruleus. Proc Natl Acad Sci USA. 1995;92(19):8788–92.

    Article  CAS  Google Scholar 

  95. Di Filippo M, Sarchielli P, Picconi B, Calabresi P. Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. Trends Pharmacol Sci. 2008;29(8):402–12.

    Article  Google Scholar 

  96. Di Filippo M, Chiasserini D, Gardoni F, Viviani B, Tozzi A, Giampà C, et al. Effects of central and peripheral inflammation on hippocampal synaptic plasticity. Neurobiol Dis. 2013;52:229–36.

    Article  Google Scholar 

  97. De Picker LJ, Morrens M, Chance SA, Boche D. Microglia and brain plasticity in acute psychosis and schizophrenia illness course: a meta-review. Front Psych. 2017;8:238.

    Article  Google Scholar 

  98. Allimuthu P, Nandeesha H, Chinniyappan R, Bhardwaz B, Blessed RJ. Relationship of brain-derived neurotrophic factor with interleukin-23, testosterone and disease severity in schizophrenia. Indian J Clin Biochem. 2021;36(3):365–9.

    Article  CAS  Google Scholar 

  99. Jesudas BR, Nandeesha H, Menon V, Allimuthu P. Relationship of elevated neural cell adhesion molecule 1 with interleukin-10 and disease severity in bipolar disorder. Asian J Psychiatr. 2020;47:101849.

    Article  Google Scholar 

  100. Chenniappan R, Nandeesha H, Kattimani S, Nanjaiah ND. Interleukin-17 and interleukin-10 association with disease progression in schizophrenia. Ann Neurosci. 2020;27(1):24–8.

    Article  Google Scholar 

  101. Gruol DL. IL-6 regulation of synaptic function in the CNS. Neuropharmacology. 2015;1(96):42–54.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, JIPMER, Puducherry, 605006, India

    Neha Keshri & Hanumanthappa Nandeesha

Authors
  1. Neha Keshri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hanumanthappa Nandeesha
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Both HN and NK equally contributed to this review with conception of the study, literature review, analysis, drafting, critical revision and approval of the final version.

Corresponding author

Correspondence to Hanumanthappa Nandeesha.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keshri, N., Nandeesha, H. Dysregulation of Synaptic Plasticity Markers in Schizophrenia. Ind J Clin Biochem 38, 4–12 (2023). https://doi.org/10.1007/s12291-022-01068-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-022-01068-2

Keywords

Search

Navigation